DMP 543Potent, orally active ACh release enhancer CAS# 160588-45-4 |
- ML347
Catalog No.:BCC5331
CAS No.:1062368-49-3
- LDN-212854
Catalog No.:BCC5330
CAS No.:1432597-26-6
- PD 169316
Catalog No.:BCC3969
CAS No.:152121-53-4
- Imperatorin
Catalog No.:BCN5574
CAS No.:482-44-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 160588-45-4 | SDF | Download SDF |
| PubChem ID | 9887884 | Appearance | Powder |
| Formula | C26H18F2N2O | M.Wt | 412.44 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 50 mM in ethanol | ||
| Chemical Name | 10,10-bis[(2-fluoropyridin-4-yl)methyl]anthracen-9-one | ||
| SMILES | C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2(CC4=CC(=NC=C4)F)CC5=CC(=NC=C5)F | ||
| Standard InChIKey | MUJBUUDUXGDXLW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C26H18F2N2O/c27-23-13-17(9-11-29-23)15-26(16-18-10-12-30-24(28)14-18)21-7-3-1-5-19(21)25(31)20-6-2-4-8-22(20)26/h1-14H,15-16H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | K+ channel blocker and acetylcholine release stimulator. Potently enhances K+-stimulated [3H]-ACh release from rat hippocampal slices (EC50 = 700 nM), and also increases release of dopamine and glutamate (EC50 values are 0.25 and 0.22 μM, respectively). Orally active in vivo; increases ACh levels in rats (with a minimum effective dose of 1 mg/kg) and exerts a long duration of action. More potent than linopirdine both in vitro and in vivo. |
DMP 543 Dilution Calculator
DMP 543 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4246 mL | 12.123 mL | 24.246 mL | 48.4919 mL | 60.6149 mL |
| 5 mM | 0.4849 mL | 2.4246 mL | 4.8492 mL | 9.6984 mL | 12.123 mL |
| 10 mM | 0.2425 mL | 1.2123 mL | 2.4246 mL | 4.8492 mL | 6.0615 mL |
| 50 mM | 0.0485 mL | 0.2425 mL | 0.4849 mL | 0.9698 mL | 1.2123 mL |
| 100 mM | 0.0242 mL | 0.1212 mL | 0.2425 mL | 0.4849 mL | 0.6061 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Zarzissine
Catalog No.:BCN6456
CAS No.:160568-14-9
- 5,7,3',4'-Tetrahydroxy-3-methoxy-8-geranylflavone
Catalog No.:BCN6847
CAS No.:1605304-56-0
- BW 723C86 hydrochloride
Catalog No.:BCC6915
CAS No.:160521-72-2
- 12S-hydroxyandrographolide
Catalog No.:BCN4700
CAS No.:869593-50-0
- Bisandrographolide A
Catalog No.:BCN4701
CAS No.:160498-00-0
- Antirhine
Catalog No.:BCN4003
CAS No.:16049-28-8
- THZ2
Catalog No.:BCC3986
CAS No.:1604810-84-5
- THZ1
Catalog No.:BCC4005
CAS No.:1604810-83-4
- 30-Oxopseudotaraxasterol
Catalog No.:BCN7135
CAS No.:160481-71-0
- 3',5,5',7-Tetrahydroxyflavanone
Catalog No.:BCN1710
CAS No.:160436-10-2
- X-NeuNAc
Catalog No.:BCC2063
CAS No.:160369-85-7
- Bisdehydroneotuberostemonine
Catalog No.:BCN7072
CAS No.:160333-27-7
- Villosin
Catalog No.:BCN1711
CAS No.:160598-92-5
- 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone
Catalog No.:BCN1548
CAS No.:160623-47-2
- 2,3-Dihydro-3alpha-methoxynimbolide
Catalog No.:BCN7093
CAS No.:1607828-35-2
- Ardisicrenoside B
Catalog No.:BCN8078
CAS No.:160791-12-8
- Indirubin-3'-oxime
Catalog No.:BCC7185
CAS No.:160807-49-8
- AMG319
Catalog No.:BCC6510
CAS No.:1608125-21-8
- H-Thr(Bzl)-ol
Catalog No.:BCC2577
CAS No.:160841-03-2
- Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate
Catalog No.:BCC8967
CAS No.:160844-75-7
- Chrysin 8-C-glucoside
Catalog No.:BCN7982
CAS No.:160880-89-7
- Fmoc-Valinol
Catalog No.:BCC2694
CAS No.:160885-98-3
- Hosenkoside F
Catalog No.:BCN2520
CAS No.:160896-45-7
- Hosenkoside G
Catalog No.:BCN2272
CAS No.:160896-46-8
Efficient pyridinylmethyl functionalization: synthesis of 10, 10-Bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone (DMP 543), an acetylcholine release enhancing agent.[Pubmed:11073571]
J Org Chem. 2000 Nov 17;65(23):7718-22.
2-Fluoro-4-methylpyridine (3) is efficiently functionalized by chlorination, hydrolysis and methanesulfonylation into the novel alkylating agent 7. This mesylate is used for the bisalkylation of anthrone under carefully defined conditions to prepare the cognition enhancer drug candidate 1. This process proceeds in up to 37% overall yield and is adaptable for large scale synthesis.
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.[Pubmed:9804701]
J Med Chem. 1998 Nov 5;41(23):4615-22.
In an effort to improve the pharmacokinetic and pharmacodynamic properties of the cognition-enhancer linopirdine (DuP 996), a number of core structure analogues were prepared in which the 4-pyridyl pendant group was systematically replaced with 2-fluoro-4-pyridyl. This strategy resulted in the discovery of several compounds with improved activity in acetylcholine (ACh) release-enhancing assays, in vitro and in vivo. The most effective compound resulting from these studies, 10, 10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone (9), is between 10 and 20 times more potent than linopirdine in increasing extracellular hippocampal ACh levels in the rat with a minimum effective dose of 1 mg/kg. In addition to superior potency, 9 possesses an improved pharmacokinetic profile compared to that of linopirdine. The half-life of 9 (2 h) in rats is 4-fold greater than that of linopirdine (0.5 h), and it showed a 6-fold improvement in brain-plasma distribution over linopirdine. On the basis of its pharmacologic, pharmacokinetic, absorption, and distribution properties, 9 (DMP543) has been advanced for clinical evaluation as a potential palliative therapeutic for treatment of Alzheimer's disease.
Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.[Pubmed:9580619]
J Pharmacol Exp Ther. 1998 May;285(2):724-30.
Linopirdine (3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one, DUP996) is an extensively studied representative of a class of cognition enhancing compounds that increase the evoked release of neurotransmitters. Recent studies suggest that these agents act through the blockade of specific K+ channels. We have recently identified more potent anthracenone analogs of linopirdine: 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE991) and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone (DMP 543). Although linopirdine possesses an EC50 of 4.2 microM for enhancement of [3H]ACh release from rat brain slices, XE991 and DMP 543 have EC50S of 490 and 700 nM, respectively. In addition to greater in vitro potency relative to linopirdine, both compounds show greater in vivo potency and duration of action. Although 5 mg/kg (p.o.) linopirdine does not lead to statistically significant increases in hippocampal extracellular acetylcholine levels, 5 mg/kg (p.o.) XE991 leads to increases (maximal effect > 90% over baseline) which are sustained for 60 min. Moreover, DMP 543 at 1 mg/kg causes more than a 100% increase in acetylcholine levels with the effect lasting more than 3 hr. At doses relevant to their release-enhancing properties, the only overt symptom consistently observed was tremor, possible via a cholinergic mechanism. These results suggest that XE991 and DMP 543 may prove to be superior to linopirdine as Alzheimer's disease therapeutics. In addition, these agents should be useful pharmacological tools for probing the importance of particular ion channels in the control of neurotransmitter release.
